Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha. [2]

The recommended dose and schedule of olaratumab is 15 mg/kg administered as an IV infusion over 60 minutes on days 1 and 8 of each 21-day cycle until disease progression or unacceptable...

Olaratumab injection is used in combination with doxorubicin to treat soft tissue sarcoma (STS) in patients who cannot be cured with radiation therapy or surgery, and need to be treated with an anthracycline-containing regimen.

LARTRUVOTM is a platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma...

2007年11月18日 · Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding.

The U.S. Food and Drug Administration (FDA) recently approved a new molecularly targeted therapeutic called olaratumab (Lartruvo) for treating certain patients with soft tissue sarcoma.

Olaratumab is a monoclonal antibody that specifically binds to platelet‐derived growth factor receptor alpha (PDGFRα) and blocks receptor activation. We conducted a phase 1 trial to evaluate the safety of olaratumab and determine a recommended dose ...

Olaratumab injection is used along with another medication to treat certain types of soft tissue sarcoma (cancer that begins in soft tissues such as muscles, fat, tendons, nerves, and blood vessels), which cannot be treated successfully with surgery or radiation.

2024年4月7日 · Easy-to-read patient leaflet for Olaratumab. Includes indications, proper use, special instructions, precautions, and possible side effects.

Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody that binds PDGFR-α with high affinity (∼40 pM) and inhibits PDGF binding to the receptor (Loizos et al., 2005).